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Abstract
Effective control of tuberculosis (TB) includes discrimination of
subjects with active TB from individuals with latent TB infection
(LTBI). As distinct interferon (IFN)-c and interleukin (IL)-2 pro-
ﬁles of antigen-speciﬁc T-cells have been associated with differ-
ent clinical stages and antigen loads in several viral and bacterial
diseases, we analysed these cytokines in TB using a modiﬁed
QuantiFERON-TB Gold In Tube test. Detection of IL-2 in addi-
tion to IFN-c distinguishes not only Mycobacterium tuberculosis-
infected subjects from healthy controls, but also individuals with
LTBI from active TB patients. This may help to improve diagnos-
tic tests for TB.
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The tuberculin skin test (TST) is the most commonly used
tool for the diagnosis of Mycobacterium tuberculosis infection,
but its speciﬁcity is limited, because the puriﬁed protein
derivative used contains more than 200 antigens that are
shared among environmental mycobacteria and bacille
Calmette–Gue´rin used for vaccination [1]. Alternatives to
TST have emerged as a new class of in vitro assays that mea-
sure interferon (IFN)-c release after stimulation of blood
cells by M. tuberculosis antigens [2–5]. These antigens include
early secreted antigenic target-6, culture ﬁltrate protein-10,
and TB7.7 (protein Rv2654), which are more speciﬁc than
puriﬁed protein derivative, as they are not shared with ba-
cille Calmette–Gue´rin or the majority of environmental
mycobacteria [6]. Thus, IFN-c release assays provide an
accurate diagnosis of M. tuberculosis infection, but they do
not discriminate patients with active tuberculosis (TB) from
individuals with latent TB infection (LTBI).
The aim of this study was to investigate whether the mea-
surement of interleukin (IL)-2 in addition to IFN-c in whole
blood stimulated with M. tuberculosis-speciﬁc antigens in the
QuantiFERON-TB Gold In Tube format would be useful for
identifying patients with different stages of disease.
The QuantiFERON-TB Gold In Tube test (Cellestis, Car-
negie, Australia) was performed according to the manufac-
turer’s instructions, and the amounts of IFN-c (expressed as
IU/mL) and IL-2 (expressed as U/mL) released were deter-
mined both after 18 h and after 72 h of incubation. Results
are expressed as the concentration of IFN-c detected minus
the concentration of cytokine in the respective nil control
plasma. IL-2 release was determined with a commercially
available ELISA assay (DRG GmbH, Germany), following the
manufacturer’s instructions.
Data were analysed using the Mann–Whitney U-test with
the fourth version of GraphPad Prism software. A p-value of
<0.05 was considered signiﬁcant. Diagnostic accuracies of
the tests were evaluated using receiver operating character-
istic (ROC) curve analysis, plotting sensitivity (%) vs.
(100% – speciﬁcity (%)), evaluated at several different diag-
nostic thresholds. The area under the curve (AUC) and the
corresponding 95% conﬁdential interval were calculated.
Optimum cut-off values, with the combination of the highest
sensitivity and speciﬁcity, were calculated.
Patients were recruited from the Infectious Diseases
Ward at the National Institute for Infectious Diseases L. Spa-
llanzani, and the Infectious Diseases Department of Sapienza
Universita` di Roma, Italy, between 2008 and 2009, and
underwent both TSTs and QuantiFERON-TB Gold In Tube
tests at the same time within a week of admission. Individu-
als were classiﬁed as having ‘active pulmonary TB’ when the
diagnosis was conﬁrmed by positive M. tuberculosis culture
from sputum specimens. We do not include in the study
patients with active TB who resulted positive to the human
immunodeﬁciency virus screening. Patients with active TB
resulting undetermined or negative to QuantiFERON-TB
Gold In Tube test were also excluded.
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LTBI was deﬁned by a positive response to the TST and
to the QuantiFERON-TB Gold In Tube test in exposed indi-
viduals without signs of active disease. Healthy controls were
laboratory personnel with no known exposure to M. tubercu-
losis (Table 1). The ethical committees of the clinical sites
approved the study, and all enrolled individuals gave their
written informed consent.
Subjects with LTBI and patients with active TB secreted
signiﬁcantly more IFN-c in response to M. tuberculosis anti-
gens than healthy controls after 18 h of incubation (Fig. 1a:
median 8.29 and 7.91 IU/mL, respectively, vs. 0.05 IU/mL) as
well as after 72 h of incubation (Fig. 1b: median 11.96 and
13.19 IU/mL for LTBI and TB patients, respectively, and
below detectable levels for the control group). The IFN-c
release was not signiﬁcantly different between the LTBI and
active TB groups. ROC curve analyses showed that neither
at 18 h (not shown) nor at 72 h (Fig. 1c) did speciﬁc IFN-c
release allow the distinction of individuals with LTBI from
patients with active TB (AUC 0.72 with 95% CI 0.5974–
0.8538; p 0.07).
M. tuberculosis-speciﬁc antigens stimulated the production
of low levels of IL-2 in LTBI individuals (Fig. 1d) at 18 h of
TABLE 1. Demographic and clinical characteristics of enrol-
led individuals
Healthy controls
n = 20
Subjects with LTBI
n = 20
Active TB
n = 20
Female sex, no. 6 8 9
Age, median (years) 31.4 42.3 35.7
Nationality
Italian, no. 20 20 9
East European, no. 0 0 11
BCG vaccinated, no. 0 0 7
TST-positive, no. 0 20 12
QTF.IT-positive, no. 0 20 20
LTBI, latent tuberculosis infection; TB, tuberculosis; BCG, bacille Calmette–
Gue´rin; TST, tuberculin skin test; QTF.IT, QuantiFERON-TB Gold In Tube.
FIG. 1. Interferon (IFN)-c release discriminates Mycobacterium tuberculosis-infected individuals from healthy controls (CTR), and interleukin (IL)-2
release discriminates active tuberculosis (Act TB) patients from subjects with latent tuberculosis infection (LTBI). IFN-c release obtained after
18 h (a) or 72 h (b) of incubation or IL-2 levels after 18 h (d) and 72 h (e) of incubation with a mixture of M. tuberculosis-speciﬁc antigens in
three different groups of subjects: healthy non-infected controls, subjects with LTBI, and patients with active tuberculosis. Horizontal bars indi-
cate the medians of the IFN-c and IL-2 values of the respective population. Data were analysed using the Mann–Whitney U-test, and differences
were considered to be signiﬁcant when the p-values (indicated by the numbers) were <0.05. (c, f) Receiver operating characteristic curve analy-
ses were performed on results obtained at 72 h by plotting sensitivity (%) vs. (100% – speciﬁcity (%)) to evaluate the effects of different thresh-
olds of measured IFN-c (c) or IL-2 (f) in LTBI subjects vs. other groups (control individuals and patients with active TB). Squares indicate the
various cut-off values used to calculate the corresponding sensitivity and speciﬁcity. The arrow indicates the optimum cut-off of IL-2 level (2.0 U/
mL) with the best combination of sensitivity and speciﬁcity.
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incubation. When the incubation was prolonged to 72 h
(Fig. 1e), the amounts of IL-2 secreted by LTBI subjects were
signiﬁcantly higher than those released by active TB patients
(p <0.0001) and healthy controls (median: 14.72 U/mL in
LTBI patients; 0.44 U/mL and 0.11 U/mL in TB patients and
healthy controls, respectively). The accuracy of the test in
discriminating LTBI subjects was then evaluated. The ROC
plot (Fig. 1f) passes very close to the favourable upper left
corner (AUC 0.99 with 95% CI 0.9734–1.007; p <0.0001),
and the threshold of 2.0 U/mL gives a sensitivity of 90% and
a speciﬁcity of 97.5%. Thus, IL-2 release by speciﬁc T-cells
after 72 h of stimulation with M. tuberculosis antigen mixture
proved its ability to discriminate LTBI individuals from
patients with active TB, in agreement with preliminary data
obtained by ﬂow cytometry [7]. Previous studies evaluating
the performance of IL-2 as an alternative or adjunct marker
of M. tuberculosis infection [8,9] have shown that this cyto-
kine is not useful as stand-alone diagnostic indicator of TB.
We conﬁrmed that the amounts of IL-2 measured at 18 h
are inadequate for discrimination of M. tuberculosis-infected
individuals, as only cells from individuals with LTBI (and not
those from individuals with active TB) secrete this cytokine
after M. tuberculosis-speciﬁc stimuli. However, when the cul-
ture is prolonged up to 3 days, IL-2 secretion increases only
in subjects with LTBI. These data are likely to reﬂect the
increased number of IL-2-secreting and IL-2/IFN-c-secreting
central memory T-cells [10,11] and the reduced number of
IFN-c-secreting effector memory T-cells in individuals with
latent TB infection in comparison with active TB patients,
owing to the absence of M. tuberculosis replication and, con-
sequently, antigen load [3,12]. Our data are in agreement
with those of Millington et al. [12] showing that IFN-c-secret-
ing T-cells predominate during active TB disease. The emer-
gence of IL-2-secreting cells in patients after antibiotic
treatment could be considered to be a consequence of the
expansion of central memory T-cells, caused by the reduced
M. tuberculosis antigen load [12], that are likely to predomi-
nate also in LTBI.
In conclusion, the results of our retrospective study, albeit
conducted in a small number of individuals, indicate that IFN-
c and IL-2 dynamic proﬁles, obtained with a simple modiﬁca-
tion of a widely utilized commercially available test, could be
used to exclude healthy individuals and, among M. tuberculo-
sis-infected subjects, to discriminate between active TB and
LTBI. A full prospective study is required to assess the diag-
nostic power of the simultaneous detection of IFN-c and
IL-2 in the diagnosis of TB and its stages.
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